Table 2.
The results of T-SPOT and blood routine examination of the study participants.
| Variables | Qiaokou (training) cohort | P* | Caidian (validation) cohort | P* | P † | ||
|---|---|---|---|---|---|---|---|
| ATB (n = 1,097) | LTBI (n = 962) | ATB (n = 372) | LTBI (n = 511) | ||||
| ESAT-6 SFC | 32 (11–93) | 14 (7–31) | <0.001 | 30 (12–98) | 12 (6–27) | <0.001 | 0.027 |
| CFP-10 SFC | 58 (14–167) | 11 (4–30) | <0.001 | 54 (15–159) | 10 (4–25) | <0.001 | <0.001 |
| WBC# (×109/L) | 6.47 (5.12–8.63) | 5.94 (5.02–7.05) | <0.001 | 6.44 (5.26–8.31) | 5.95 (5.08–7.16) | <0.001 | 0.553 |
| NEUT% (%) | 69.2 (61.8–76.4) | 58.5 (53.2–64.3) | <0.001 | 69.2 (62.5–75.7) | 59.6 (53.7–64.6) | <0.001 | 0.073 |
| NEUT# (×109/L) | 4.46 (3.25–6.26) | 3.46 (2.74–4.33) | <0.001 | 4.48 (3.32–6.13) | 3.49 (2.81–4.47) | <0.001 | 0.306 |
| LYMPH% (%) | 20.1 (13.6–26.5) | 30.3 (25.0–36.1) | <0.001 | 19.5 (13.8–25.8) | 29.9 (25.2–34.8) | <0.001 | 0.078 |
| LYMPH# (×109/L) | 1.24 (0.92–1.67) | 1.79 (1.48–2.14) | <0.001 | 1.23 (0.91–1.62) | 1.74 (1.49–2.07) | <0.001 | 0.129 |
| MONO% (%) | 8.1 (6.3–10.0) | 7.4 (6.3–8.8) | <0.001 | 8.3 (6.4–10.4) | 7.7 (6.4–9.0) | <0.001 | 0.329 |
| MONO# (×109/L) | 0.51 (0.38–0.70) | 0.45 (0.36–0.55) | <0.001 | 0.53 (0.39–0.69) | 0.45 (0.37–0.55) | <0.001 | 0.853 |
| EO% (%) | 1.2 (0.5–2.4) | 2.1 (1.2–3.3) | <0.001 | 1.2 (0.4–2.3) | 1.9 (1.1–3.1) | <0.001 | 0.736 |
| EO# (×109/L) | 0.07 (0.03–0.15) | 0.12 (0.07–0.20) | <0.001 | 0.08 (0.03–0.15) | 0.12 (0.06–0.19) | <0.001 | 0.661 |
| BASO% (%) | 0.3 (0.2–0.5) | 0.4 (0.2–0.6) | <0.001 | 0.3 (0.2–0.5) | 0.4 (0.2–0.6) | <0.001 | 0.098 |
| BASO# (×109/L) | 0.02 (0.01–0.03) | 0.02 (0.01–0.04) | <0.001 | 0.02 (0.01–0.03) | 0.02 (0.02–0.03) | <0.001 | 0.097 |
| RBC# (×1012/L) | 4.30 (3.89–4.67) | 4.53 (4.18–4.92) | <0.001 | 4.26 (3.97–4.67) | 4.54 (4.18–4.91) | <0.001 | 0.097 |
| HGB (g/L) | 125 (113–137) | 137 (126–150) | <0.001 | 126 (113–138) | 137 (126–150) | <0.001 | 0.01 |
| HCT (%) | 37.8 (34.2–41.2) | 40.9 (37.7–44.4) | <0.001 | 37.9 (34.4–41.2) | 41.2 (37.7–44.5) | <0.001 | 0.019 |
| MCV (fl) | 88.2 (84.8–91.8) | 90.4 (87.8–93.2) | <0.001 | 87.9 (84.3–91.6) | 90.5 (87.7–92.8) | <0.001 | 0.695 |
| MCH (pg) | 29.3 (27.9–30.6) | 30.3 (29.4–31.3) | <0.001 | 29.2 (27.9–30.6) | 30.3 (29.3–31.3) | <0.001 | 0.335 |
| MCHC (g/L) | 332 (321–340) | 335 (328–341) | <0.001 | 331 (323–340) | 335 (329–342) | <0.001 | 0.16 |
| RDW-CV | 13.4 (12.7–14.2) | 12.9 (12.4–13.3) | <0.001 | 13.3 (12.6–14.2) | 12.8 (12.3–13.3) | <0.001 | 0.007 |
| RDW-SD (fl) | 42.9 (40.3–45.6) | 42.4 (40.4–44.2) | <0.001 | 42.7 (40.1–46.2) | 42.1 (40.5–43.9) | 0.010 | 0.158 |
| PLT# (×109/L) | 235 (177–296) | 215 (180–254) | <0.001 | 242 (187–311) | 216 (184–257) | <0.001 | 0.393 |
| PDW (fl) | 11.8 (10.3–14.0) | 12.5 (11.2–14.4) | <0.001 | 11.9 (10.3–13.5) | 12.5 (11.2–14.3) | <0.001 | 0.752 |
| MPV (fl) | 10.1 (9.4–11.1) | 10.5 (9.9–11.4) | <0.001 | 10.1 (9.4–10.9) | 10.5 (9.8–11.3) | <0.001 | 0.776 |
| PLCR (%) | 26.6 (20.7–34.2) | 29.6 (24.3–36.6) | <0.001 | 26.7 (20.4–32.6) | 29.2 (24.0–36.0) | <0.001 | 0.793 |
| PCT (%) | 0.24 (0.19–0.29) | 0.23 (0.19–0.26) | 0.002 | 0.24 (0.20–0.30) | 0.23 (0.19–0.27) | <0.001 | 0.459 |
ATB, active tuberculosis; LTBI, latent tuberculosis infection; TB, tuberculosis; ESAT-6, early secreted antigenic target 6; CFP-10, culture filtrate protein 10; SFC, spot-forming cells; WBC#, white blood cell count; NEUT%, neutrophil percentage; NEUT#, neutrophil count; LYMPH%, lymphocyte percentage; LYMPH#, lymphocyte count; MONO%, monocyte percentage; MONO#, monocyte count; EO%, eosinophil percentage; EO#, eosinophil count; BASO%, basophil percentage; BASO#, basophil count; RBC#, red blood cell count; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW-CV, coefficient variation of red blood cell volume distribution width; RDW-SD, standard deviation in red cell distribution width; PLT#, platelet count; PDW, platelet distribution width; MPV, mean platelet volume; PLCR, platelet larger cell ratio; PCT, thrombocytocrit. *Comparisons were performed between ATB and LTBI groups using chi-square test or Mann-Whitney U test. †Comparisons were performed between Qiaokou and Caidian cohorts using chi-square test or Mann-Whitney U test. Data were presented as medians (25th–75th percentages).